How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

312 results for

Constitutional Short Stature

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

301. Final height in boys with untreated constitutional delay in growth and puberty. Full Text available with Trip Pro

Final height in boys with untreated constitutional delay in growth and puberty. To determine the natural history and psychological impact of the growth pattern in boys with constitutional delay in growth and puberty (CDGP), 43 boys presenting with short stature due to CDGP were followed up to final height. At presentation mean (SD) chronological age was 14.0 (1.9) years, bone age delay 2.7 (1.0) years, standing height standard deviation score (SDS) -3.4 (0.6), and predicted adult height SDS (...) delay had affected their success either at school, work, or socially and 20 would rather have had treatment to advance their growth spurt. This study supports the more frequent use of active medical treatment to advance growth in boys with CDGP, and shows that although boys with CDGP reach their predicted heights, this is short for their families.

1990 Archives of Disease in Childhood

302. Constitutional deletion of chromosome 20q in two patients affected with albright hereditary osteodystrophy. (Abstract)

Constitutional deletion of chromosome 20q in two patients affected with albright hereditary osteodystrophy. Albright hereditary osteodystrophy (AHO) results from heterozygous inactivation of G(s)alpha, encoded by the GNAS1 locus on the distal long arm of chromosome 20. This autosomal dominant condition is characterized by short stature, obesity, shortening of the metacarpals and metatarsals, and variable mental retardation and may also include end-organ resistance to multiple hormones. Small (...) insertions and deletions or point mutations of GNAS1 are found in approximately 80% of patients with AHO. The remainder may be accounted for by larger genomic rearrangements, but none have been reported to date. We now describe two patients with constitutional 20q deletions and features of AHO. Such deletions are rare in the published literature and have not previously been associated with AHO. Molecular genetic analysis confirmed complete deletion of GNAS1 in both patients. Parental origin could

2002 American Journal of Medical Genetics

303. Familial combined pituitary hormone deficiency due to a novel mutation R99Q in the hot spot region of Prophet of Pit-1 presenting as constitutional growth delay. Full Text available with Trip Pro

, thyrotrophs, and gonadotrophs), and PROP-1 gene mutations may interfere with the development of these cells, resulting in CPHD. We performed molecular analyses of the PROP-1 gene in two siblings, born to consanguineous parents, who presented with short stature. The index patient, a boy, was initially diagnosed with constitutional growth delay based on familial short stature, low parental target height, normal GH secretion, and imaging of the pituitary gland. On follow-up, auxological data and pubertal (...) Familial combined pituitary hormone deficiency due to a novel mutation R99Q in the hot spot region of Prophet of Pit-1 presenting as constitutional growth delay. Combined pituitary hormone deficiency (CPHD) is characterized by impaired production of GH and one or more of the other anterior pituitary hormones. Prophet of Pit-1 (PROP-1), one of the pituitary specific homeodomain transcription factors, is involved in the differentiation of the anterior pituitary cells (somatotrophs, lactotrophs

2003 Journal of Clinical Endocrinology and Metabolism

304. Method for the earlier recognition of abnormal stature. Full Text available with Trip Pro

--but the rest had genetic short stature or 'constitutional' delay in puberty. Many children who could have been treated effectively were referred too late, for effective treatment to ensure normal adult height because of this we have developed full sized percentile charts to screen populations of children so that abnormal stature can be recognised immediately. (...) Method for the earlier recognition of abnormal stature. Two hundred and twenty seven children with a height below the 3rd or above the 97th centile were seen consecutively in the Oxford growth clinic. Their referral ages were analysed to determine the pattern of referral. Eighty seven per cent of the children had short stature. In 40% of these there was an organic reason for abnormal growth--the most common conditions being growth hormone deficiency, hypothyroidism, and Turner's syndrome

1983 Archives of Disease in Childhood

305. rhGH and rhIGF-1 Combination Therapy in Children With Short Stature Associated With IGF-1 Deficiency

rhGH and rhIGF-1 Combination Therapy in Children With Short Stature Associated With IGF-1 Deficiency rhGH and rhIGF-1 Combination Therapy in Children With Short Stature Associated With IGF-1 Deficiency - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please (...) remove one or more studies before adding more. rhGH and rhIGF-1 Combination Therapy in Children With Short Stature Associated With IGF-1 Deficiency The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT00572156 Recruitment Status : Terminated (The study was prematurely terminated due to strategic reasons

2007 Clinical Trials

306. What are the causes of short stature and what investigations need to be done?

: "chronic disease (including undernutrition genetic disorders), familial short stature, and constitutional delay of growth and development. Endocrine diseases are rare causes of short stature. The hallmark of endocrine disease is linear GF occurring to a greater degree than weight loss. Most short children evaluated by clinicians in developed countries have familial short stature and/or constitutional delay of growth, both of which are diagnoses of exclusion. The hallmarks of familial short stature (...) (also referred to as genetic short stature) include bone age appropriate for chronologic age, normal growth velocity, and predicted adult height appropriate to the familial pattern (using the Bayley-Pinneau or Tanner-Goldstein-Whitehouse tables). By contrast, constitutional delay is characterized by delayed bone age, normal growth velocity, and predicted adult height appropriate to the familial pattern. Patients with constitutional delay typically have a first-degree or second-degree relative

2003 TRIP Answers

307. The effect of short-term growth hormone or low-dose oxandrolone treatment in boys with constitutional growth delay. (Abstract)

The effect of short-term growth hormone or low-dose oxandrolone treatment in boys with constitutional growth delay. We evaluated the effect of six-month treatment with growth hormone (GH) or low-dose oxandrolone in a group of boys with constitutional growth delay (CGD). Sixteen boys were randomly assigned to two treatment groups. Group 1 received GH (0.6 U/kg/week sc 5-6 times/week) and Group 2 received oxandrolone (0.07 mg/kg po). The boys of the two groups were closely matched for age (13.7 (...) +/- 0.5 and 12.8 +/- 0.4 years) (mean +/- SE), chronologic age/bone age ratio (1.15 +/- 0.04 and 1.16 +/- 0.02), height standard deviation score (SDS; -2.7 +/- 0.4 and -2.5 +/- 0.3) and pretreatment height velocity (HV) (3.7 +/- 0.8 and 4.0 +/- 0.4 cm/year). Other known causes of short stature were excluded in all subjects, and none had taken long-term medication prior to the study. After 6 months of treatment HV increased to 7.5 +/- 0.4 and to 8.1 +/- 0.5 cm/year in group 1 and 2, respectively

1991 Journal of endocrinological investigation Controlled trial quality: uncertain

308. Idiopathic short stature: results of a one-year controlled study of human growth hormone treatment. Genentech Collaborative Study Group. (Abstract)

, whereas untreated children's growth rate did not change significantly (4.2 +/- 1.3 vs 5.0 +/- 1.4 cm/yr). There was a 1-year advance in bone age for each group; thus there was a significant increase in the predicted height of the treated but not the control group. Among the treated children, the growth response did not differ among those classified on the basis of parental height and bone age as having familial short stature or constitutional delay of growth and development. Prestudy anthropomorphic (...) Idiopathic short stature: results of a one-year controlled study of human growth hormone treatment. Genentech Collaborative Study Group. A multicenter randomized trial of human growth hormone treatment was carried out in 121 children with short stature who did not meet the classic criteria for growth hormone deficiency. Patients treated for 1 year with recombinant somatropin, 0.1 mg/kg three times a week, had a significant increase in mean growth rate from 4.6 +/- 1.1 to 7.5 +/- 1.2 cm/yr

1989 The Journal of pediatrics Controlled trial quality: uncertain

309. Short Stature in Childhood and Adolescence: Part 1: Medical management Full Text available with Trip Pro

Short Stature in Childhood and Adolescence: Part 1: Medical management Childhood short stature is common in family practice. Familial short stature and constitutional growth delay account for most cases, and there are clear guidelines for differentiating these from each other and from less common pathologic conditions. Appropriate investigation, treatment, and referral are delineated, and growth hormone therapy is described. An integrated medical-psychosocial approach to care is recommended.

1991 Canadian Family Physician

310. Novel treatment of short stature with aromatase inhibitors. (Abstract)

Novel treatment of short stature with aromatase inhibitors. Estrogens have an essential role in the regulation of bone maturation and importantly in the closure of growth plates in both sexes. This prospective, randomized, placebo-controlled study was undertaken to evaluate whether suppression of estrogen synthesis in pubertal boys delays bone maturation and ultimately results in increased adult height. A total of 23 boys with constitutional delay of puberty (CDP) received a conventional, low

2003 The Journal of steroid biochemistry and molecular biology Controlled trial quality: uncertain

311. Loss of constitutive activity of the growth hormone secretagogue receptor in familial short stature Full Text available with Trip Pro

Loss of constitutive activity of the growth hormone secretagogue receptor in familial short stature The growth hormone (GH) secretagogue receptor (GHSR) was cloned as the target of a family of synthetic molecules endowed with GH release properties. As shown recently through in vitro means, this receptor displays a constitutive activity whose clinical relevance is unknown. Although pharmacological studies have demonstrated that its endogenous ligand--ghrelin--stimulates, through the GHSR, GH (...) secretion and appetite, the physiological importance of the GHSR-dependent pathways remains an open question that gives rise to much controversy. We report the identification of a GHSR missense mutation that segregates with short stature within 2 unrelated families. This mutation, which results in decreased cell-surface expression of the receptor, selectively impairs the constitutive activity of the GHSR, while preserving its ability to respond to ghrelin. This first description, to our knowledge

2006 Journal of Clinical Investigation

312. Differences in physical characteristics, perinatal histories, and social backgrounds between children with growth hormone deficiency and constitutional short stature. Full Text available with Trip Pro

Differences in physical characteristics, perinatal histories, and social backgrounds between children with growth hormone deficiency and constitutional short stature. Four hundred and forty-nine children with heights below -2.5 SD were identified by screening for height a total population of 48221 in three Scottish cities. Children participating in the study could be classified into 5 groups: severe growth hormone deficiency (n = 13), partial growth hormone deficiency (n = 25), low birthweight (...) short stature (n = 34), constitutional short stature (n = 178), and short stature associated with some underlying disease (n = 106). Children with growth hormone deficiency tended to be shorter, were more likely to be obese, were growing more slowly, more often were the products of an abnormal pregnancy, and were less socially disadvantaged than constitutionally short children. Their parents were also more likely to have sought medical advice about the short stature. These findings have important

1981 Archives of Disease in Childhood

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>